{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T06:25:05Z","timestamp":1775715905686,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,11,6]],"date-time":"2006-11-06T00:00:00Z","timestamp":1162771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2007,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p> <jats:italic>Background and aim:<\/jats:italic>\u2002Only 20\u201330% of elderly patients with acute lymphoblastic leukemia (ALL) are enrolled in clinical trials because of co\u2010morbid disorders or poor performance status. We present the results of treatment of Philadelphia chromosome\u2010negative (Ph\u2212) ALL patients over 55\u2003yr treated in the PETHEMA ALL\u201096 trial. <jats:italic>Patients and methods:<\/jats:italic>\u2002From 1996 to 2006, 33 patients 55\u2003yr with Ph\u2212 ALL were included. Induction therapy was vincristine, daunorubicin, prednisone, asparaginase, and cyclophosphamide over 5\u2003weeks. Central nervous system (CNS) prophylaxis involved triple intrathecal (IT) therapy, 14 doses over the first year. Consolidation\u20101 included mercaptopurine, methotrexate, teniposide and cytarabine, followed by one consolidation\u20102 cycle similar to the induction cycle. Maintenance consisted of mercaptopurine and methotrexate up to 2\u2003yr in complete remission (CR) with monthly reinduction cycles (vincristine, prednisone and asparaginase) during the first year. <jats:italic>Results:<\/jats:italic>\u2002Median (range) age was 65\u2003yr (56\u201377). Phenotype (30 patients): early\u2010pre\u2010B 7, common\/pre\u2010B 18, T 5. Cytogenetics (28 patients): normal 12, complex 10, t(4;11) 2 and other 4. CR was achieved in 19\/33 (57.6%) patients, early death occurred in 12 (36.4%) and 2 (6%) were resistant.  Overall survival and disease\u2010free survival probabilities (2\u2003yr, 95% CI) were 39% (21%\u201357%) and 46% (22%\u201370%), respectively (median follow up of 24 months). Removal of asparaginase and cyclophosphamide from the induction decreased induction death (OR 0.119, CI 95% 0.022\u20130.637, <jats:italic>P<\/jats:italic>\u2003=\u20030.013) and increased survival (20% vs. 52%, <jats:italic>P<\/jats:italic>\u2003=\u20030.05). <jats:italic>Conclusions:<\/jats:italic>\u2002The prognosis of elderly Ph\u2212 ALL patients is poor. In this study, less intensive induction decreased toxic death, allowing delivery of planned consolidation therapy and increased survival probability.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2006.00778.x","type":"journal-article","created":{"date-parts":[[2006,11,6]],"date-time":"2006-11-06T09:04:57Z","timestamp":1162803897000},"page":"102-110","source":"Crossref","is-referenced-by-count":66,"title":["Results of the PETHEMA ALL\u201096 trial in elderly patients with Philadelphia chromosome\u2010negative acute lymphoblastic leukemia"],"prefix":"10.1111","volume":"78","author":[{"given":"Juan\u2010Manuel","family":"Sancho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep\u2010Maria","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Xicoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Morgades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Tormo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eloy del","family":"Potro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Deb\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Abella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concepci\u00f3n","family":"Bethencourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Ort\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salut","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Ortega\u2010Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Novo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas\u2010Mar\u00eda","family":"Hern\u00e1ndez\u2010Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel\u2010Angel","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evarist","family":"Feliu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the PETHEMA Group, Barcelona, Spain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,11,6]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"533","volume-title":"American Society of Clinical Oncology Educational Book","author":"Hoelzer D","year":"2005"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.131"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200421120-00003"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000139648"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1976.tb03563.x"},{"key":"e_1_2_6_8_2","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)","volume":"9","author":"Bene MC","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.2307\/2529177"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930901)72:5<1602::AID-CNCR2820720518>3.0.CO;2-4"},{"key":"e_1_2_6_12_2","first-page":"528","volume-title":"American Society of Clinical Oncology Educational Book","author":"Appelbaum FR","year":"2005"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409049625"},{"key":"e_1_2_6_14_2","first-page":"1643","article-title":"Acute lymphoblastic leukaemia in the elderly: results of two different treatment approaches in 49 patients during a 25\u2010year period","volume":"9","author":"Ferrari A","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.952909.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.1083"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0808-9"},{"issue":"2","key":"e_1_2_6_18_2","first-page":"S134","article-title":"Results of PETHEMA ALL\u201096 protocol for standard risk adult ALL patients","volume":"5","author":"Ribera JM","year":"2004","journal-title":"Hematology J"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04982.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01696557"},{"key":"e_1_2_6_21_2","first-page":"3135","article-title":"Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative study of the Groupe Fran\u00e7ais de Cytogenetique Hematologique","volume":"87","author":"Groupe Fran\u00e7ais de Cytogenetique Hematologique","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190210180"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood.V80.7.1813.1813","article-title":"Acute lymphoblastic leukemia in patients aged 60\u2003years and over: a population\u2010based study of incidence and outcome","volume":"80","author":"Taylor PRA","year":"1992","journal-title":"Blood"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400780"},{"key":"e_1_2_6_25_2","first-page":"1327","article-title":"Acute lymphoblastic leukemia in the elderly. A twelve\u2010year retrospective, single center study","volume":"85","author":"Pagano L","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609051761"},{"issue":"1","key":"e_1_2_6_27_2","first-page":"718a","article-title":"Results of a shortened, dose reduced treatment protocol in elderly patients with acute lymphoblastic leukaemia [abstract]","volume":"96","author":"G\u00f6kbuget N","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.547"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190400019917"},{"key":"e_1_2_6_30_2","first-page":"1556","article-title":"A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB Study 9111","volume":"92","author":"Larson RA","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"521a","DOI":"10.1182\/blood.V106.11.1831.1831","article-title":"Update of the modified Hyper\u2010CVAD regimen with or without rituximab in newly diagnosed adult acute lymphocytic leukemia [abstract]","volume":"106","author":"Thomas DA","year":"2005","journal-title":"Blood"},{"issue":"1","key":"e_1_2_6_32_2","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/blood.V104.11.2732.2732","article-title":"Subtype adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia (ALL)","volume":"104","author":"Hoelzer D","year":"2004","journal-title":"Blood"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2006.00778.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2006.00778.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T23:05:04Z","timestamp":1696979104000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2006.00778.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,6]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["10.1111\/j.1600-0609.2006.00778.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2006.00778.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,6]]}}}